GlassScriptPhysician profile
Satish Dasari
NPI 1811996606
$4,758.38
in general payments reported to CMS, 2019-2025
30 companies · $799 in 2025
The $799 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $834 · 2020: $1,280 · 2021: $353 · 2022: $427 · 2023: $674 · 2024: $393 · 2025: $799.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,122.38 | 2021-2025 | Intellis Adaptivestim, Accurian, Vanta Adaptivestim |
| Nalu Medical, INC. | $856.40 | 2020 | |
| Abbott Laboratories | $674.14 | 2019-2025 | Proclaim |
| Boston Scientific Corporation | $271.00 | 2019-2025 | Intracept Rf Probe, Intracept |
| Medtronic USA, INC. | $175.34 | 2019-2020 | |
| Vertos Medical, INC. | $164.32 | 2021-2023 | Mild Device Kit |
| Globus Medical, INC. | $141.52 | 2025 | Senza |
| Scilex Pharmaceuticals INC. | $135.60 | 2019-2025 | |
| Painteq LLC | $134.71 | 2023 | Painteq |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Mml US, INC. | $124.18 | 2024-2025 | Reactiv8 |
| Collegium Pharmaceutical, INC. | $117.67 | 2019-2025 | Belbuca, Xtampza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.00 | 2019 | |
| Nevro Corp. | $90.14 | 2019-2023 | Senza |
| Stryker Corporation | $86.43 | 2022-2025 | Spinejack |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $65.44 | 2019-2020 | |
| Relievant Medsystems, INC. | $55.67 | 2020 | |
| Biodelivery Sciences International, INC. | $44.80 | 2019-2021 | |
| Almatica Pharma LLC | $42.17 | 2021 | |
| Assertio Therapeutics, INC. | $35.01 | 2019 | |
| Myoscience INC. | $27.70 | 2019 | |
| Convatec INC. | $27.17 | 2024 | |
| Pacira Therapeutics, INC. | $20.83 | 2021 | |
| Saluda Medical Americas, INC. | $20.50 | 2025 | Evoke |
| Curonix LLC | $19.18 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Si-Bone, INC. | $16.61 | 2022 | |
| Azurity Pharmaceuticals, INC. | $15.86 | 2023 | Horizant |
| Vertiflex, INC. | $14.44 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.06 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Dasari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.